公開日期 | 標題 | 作者 | 來源出版物 | WOS | 全文 |
2002 | Analysis of IgG Fc receptor Fc gamma RIIIa polymorphism in relapsed follicular non-Hodgkin's lymphoma patients treated with Rituximab | Wen-Kai Weng ; Levy, R. | Blood | | |
2003 | Analysis of tumor-specific T cell immune response in follicular non-Hodgkin's lymphoma patients treated with rituximab | Wen-Kai Weng ; Levy, R. | Blood | | |
2020 | Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial | Frank, M. J.; Khodadoust, M. S.; Czerwinski, D. K.; Haabeth, O. A. W.; Chu, M. P.; Miklos, D. B.; Advani, R. H.; Alizadeh, A. A.; Gupta, N. K.; Maeda, L. S.; Reddy, S. A.; Laport, G. G.; Meyer, E. H.; Negrin, R. S.; Rezvani, A. R.; Wen-Kai Weng ; Sheehan, K.; Faham, M.; Okada, A.; Moore, A. H.; Phillips, D. L.; Wapnir, I. L.; Brody, J. D.; Levy, R. | Journal of Experimental Medicine | | |
2013 | Cancer Vaccines and T Cell Therapy | Rezvani, K.; Brody, J. D.; Kohrt, H. E.; Logan, A. C.; Advani, R.; Czerwinski, D. K.; Wen-Kai Weng ; Negrin, R. S.; Carlton, V.; Faham, M.; Levy, R.; Barrett, J. | Biology of Blood and Marrow Transplantation | | |
2013 | Cancer Vaccines and T Cell Therapy (vol 19, pg S97, 2013) | Rezvani, K.; Brody, J. D.; Kohrt, H. E.; Logan, A. C.; Advani, R.; Czerwinski, D. K.; Wen-Kai Weng ; Negrin, R. S.; Carlton, V.; Faham, M.; Levy, R.; Barrett, J. | Biology of Blood and Marrow Transplantation | | |
2004 | Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype | Wen-Kai Weng ; Czerwinski, D.; Timmerman, J.; Hsu, F. J.; Levy, R. | Journal of Clinical Oncology | | |
2012 | Effect of stimulation of natural killer cells with an anti-CD137 mAb on the efficacy of trastuzumab, cetuximab, and rituximab | Kohrt, H. E.; Houot, R.; Weiskopf, K.; Goldstein, M.; Lund, P.; Scheeren, F.; Czerwinski, D.; Colevas, A. D.; Wen-Kai Weng ; Clarke, M. F.; Carlson, R. W.; Sunwoo, J.; Tedder, T.; Chen, L. P.; Levy, R. | Journal of Clinical Oncology | | |
2001 | Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma | Wen-Kai Weng ; Levy, R. | Blood | | |
2004 | Fc-gamma R IIIa polymorphism and anti-idiotype humoral immune response predict clinical outcome in follicular lymphoma patients receiving idiotypic vaccination | Wen-Kai Weng ; Czerwinski, D.; Levy, R. | Journal of Clinical Oncology | | |
2005 | Genetic polymorphism of the inhibitory IgG Fc receptor Fc gamma RIIb is not associated with clinical outcome of rituximab treated follicular lymphoma patients | Wen-Kai Weng ; Levy, R. | Blood | | |
2009 | Genetic polymorphism of the inhibitory IgG Fc receptor FcRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab | Wen-Kai Weng ; Levy, R. | Leukemia & Lymphoma | | |
2001 | Human anti-CD40 antagonistic antibodies, inhibit the proliferation of human B cell non-Hodgkin's lymphoma | Wen-Kai Weng ; Wang, C. Y.; Chu, K. T.; Levy, R. | Blood | | |
2005 | Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy | Wen-Kai Weng ; Czerwinski, D.; Levy, R. | Blood | | |
2007 | Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphorna patients regardless of their response to induction chemotherapy | Wen-Kai Weng ; Czerwinski, D.; Levy, R. | Blood | | |
2004 | Immunoglobulin G Fc receptor polymorphisms and clinical course in follicular lymphoma patients | Wen-Kai Weng ; Rosenberg, A.; Levy, R. | Blood | | |
2009 | Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma | Wen-Kai Weng ; Levy, R. | Leukemia & Lymphoma | | |
2011 | Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results | Brody, J. D.; Czerwinski, D. K.; Carlton, V.; Moorhead, M.; Zheng, J. B. A.; Klinger, M.; Faham, M.; Advani, R.; Kohrt, H. E.; Alizadeh, A. A.; Negrin, R. S.; Weng, WK ; Sheehan, K.; Levy, R. | Blood | 0 | |
2006 | The long term clinical outcome of B cell lymphoma patients treated with anti-idiotype monoclonal antibody correlated with the isotype of the therapeutic antibody | Wen-Kai Weng ; Czerwinski, D.; Levy, R. | Blood | | |
2015 | Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis | Chu, M. P.; Brody, J.; Kohrt, H. E.; Frank, M. J.; Khodadoust, M.; Reddy, S.; Advani, R. H.; Gupta, N. K.; Laport, G.; Maeda, L. S.; Meyer, E.; Miklos, D. B.; Negrin, R.; Rezvani, A. R.; Wen-Kai Weng ; Sheehan, K.; Faham, M.; Czerwinski, D. K.; Okada, A.; Levy, R. | Blood | | |
2005 | A polymorphism in the C1qA component of complement correlates with prolonged complete remission following rituximab therapy of follicular lymphoma | Racila, E.; Wen-Kai Weng ; Wooldridge, J. E.; Link, B. K.; Levy, R.; Weiner, G. J. | Blood | | |